liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Blood chemistry markers for evaluation of inflammatory activity in Crohns disease during infliximab therapy
Karolinska University Hospital.
Linköping University, Department of Clinical and Experimental Medicine, Clinical Chemistry. Linköping University, Faculty of Health Sciences. Östergötlands Läns Landsting, Centre for Laboratory Medicine, Department of Clinical Chemistry.
Karolinska University Hospital.
Merck Sharp and Dohme Ltd.
Show others and affiliations
2011 (English)In: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, ISSN 0036-5521, Vol. 46, no 4, 420-427 p.Article in journal (Refereed) Published
Abstract [en]

Objective. There is a discrepancy between clinical activity and biomarkers in inflammatory bowel disease. The Harvey--Bradshaw index (HBi) is steadfast to evaluate disease activity. A set of biological markers (high sensitive C-reactive protein [hs-CRP], calprotectin, total nitrite, soluble urokinase Plasminogen Activator Receptor [suPAR], ghrelin and endothelin) are investigated to study inflammatory activity and correlation with HBi during infliximab therapy. Material and methods. Patients with Crohnsdisease (n == 22) were assessed and blood samples drawn before and 1 week after infliximab infusion (5 mg/kg) and repeated after 6 months, and compared to healthy volunteers. Hs-CRP, calprotectin, suPAR, ghrelin and endothelin were analyzed with immunoassays, and total nitrite with Griess-reaction. Results were analyzed with Wilcoxon matched-pairs test, Mann--Whitney test and Spearman correlations. Results. After the first infusion visit, HBi and calprotectin values decreased while nitrite increased (p andlt; 0.05). At the 6-month visit, pre-infusion index and biomarkers had returned to baseline levels. Post-infusion, again the values of HBi, hs-CRP and calprotectin decreased (p andlt; 0.05). The suPAR levels did not change between pre- and post-infusion periods at either visit. Calprotectin, nitrite and suPAR differed from healthy controls throughout the study (p andlt; 0.05). Endothelin decreased with each treatment but was, like ghrelin, not different from controls. We found HBi to correlate with hs-CRP (Spearman r == 0.32, p andlt; 0.05), but calprotectin did not, neither did nitrate nor suPAR. Conclusions. Although infliximab ameliorates Crohnsdisease symptoms, inflammatory markers are not persistently normalized, indicating a chronic inflammatory condition that may require continued infliximab therapy.

Place, publisher, year, edition, pages
Informa Healthcare , 2011. Vol. 46, no 4, 420-427 p.
Keyword [en]
Biological treatment, biomarkers, Harvey-Bradshaw index, inflammatory bowel disease
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-67007DOI: 10.3109/00365521.2010.539253ISI: 000288170600006OAI: diva2:406261
Available from: 2011-03-25 Created: 2011-03-25 Last updated: 2011-04-21

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Theodorsson, Elvar
By organisation
Clinical ChemistryFaculty of Health SciencesDepartment of Clinical Chemistry
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 10 hits
ReferencesLink to record
Permanent link

Direct link